Integrated Microarray to Identify the Hub MiRNAs and Constructed MiRNA-mRNA Network in Neuroblastoma Via Bioinformatics Analysis

Overview

Journal Neurochem Res

Specialties Chemistry
Neurology

Date 2020 Oct 26

PMID 33104965

Citations 6

Authors

Bo Chen

Zhongyan Hua

Xiuni Qin

Zhijie Li

Affiliations

Soon will be listed here.

Abstract

Neuroblastomas (NB) are childhood malignant tumors originating in the sympathetic nervous system. MicroRNAs (miRNAs) play an essential regulatory role in tumorigenesis and development. In this study, NB miRNA and mRNA expression profile data in the Gene Expression Omnibus database were used to screen for differentially expressed miRNAs (DEMs) and genes (DEGs). We used the miRTarBase and miRSystem databases to predict the target genes of the DEMs, and we selected target genes that overlapped with the DEGs as candidate genes for further study. Annotations, visualization, and the DAVID database were used to perform Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis on the candidate genes. Additionally, the protein-protein interaction (PPI) network and miRNA-mRNA regulatory network were constructed and visualized using the STRING database and Cytoscape, and the hub modules were analyzed for function and pathway enrichment using the DAVID database and BiNGO plug-in. 107 DEMs and 1139 DEGs were identified from the miRNA and mRNA chips, respectively. 4390 overlapping target genes were identified using the two databases, and 405 candidate genes which intersected with the DEGs were selected. These candidate genes were enriched in 363 GO terms and 24 KEGG pathways. By constructing a PPI network and a miRNA-mRNA regulatory network, three hub miRNAs (hsa-miR-30e-5p, hsa-miR-15a, and hsa-miR-16) were identified. The target genes of the hub miRNAs were significantly enriched in the following pathways: microRNAs in cancer, the PI3K-Akt signaling pathway, pathways in cancer, the p53 signaling pathway, and the cell cycle. In summary, our results have identified candidate genes and pathways related to the underlying molecular mechanism of NB. These findings provide a new perspective for NB research and treatment.

Citing Articles

Integrated Transcriptome Profiling Identifies Prognostic Hub Genes as Therapeutic Targets of Glioblastoma: Evidenced by Bioinformatics Analysis.

Nayak C, Singh S ACS Omega. 2022; 7(26):22531-22550.

PMID: 35811900 PMC: 9260928. DOI: 10.1021/acsomega.2c01820.

Antioxidant Effects and Potential Molecular Mechanism of Action of Extract Based on Systematic Network Pharmacology.

Yang Z, Mo Y, Cheng F, Zhang H, Shang R, Wang X Front Vet Sci. 2022; 8:775490.

PMID: 35071383 PMC: 8767100. DOI: 10.3389/fvets.2021.775490.

A regulatory miRNA-mRNA network is associated with transplantation response in acute kidney injury.

Guo D, Fan Y, Yue J, Lin T Hum Genomics. 2021; 15(1):69.

PMID: 34886903 PMC: 8656037. DOI: 10.1186/s40246-021-00363-y.

Multi-omics network characterization reveals novel microRNA biomarkers and mechanisms for diagnosis and subtyping of kidney transplant rejection.

Lin Y, Wang L, Ge W, Hui Y, Zhou Z, Hu L J Transl Med. 2021; 19(1):346.

PMID: 34389032 PMC: 8361655. DOI: 10.1186/s12967-021-03025-8.

Long Noncoding RNA LINC01410 Suppresses Tumorigenesis and Enhances Radiosensitivity in Neuroblastoma Cells Through Regulating miR-545-3p/HK2 Axis.

Mou L, Wang L, Zhang S, Wang Q Onco Targets Ther. 2021; 14:3225-3238.

PMID: 34040388 PMC: 8140916. DOI: 10.2147/OTT.S297969.

References

Gains J, Sebire N, Moroz V, Wheatley K, Gaze M . Immunohistochemical evaluation of molecular radiotherapy target expression in neuroblastoma tissue. Eur J Nucl Med Mol Imaging. 2017; 45(3):402-411. DOI: 10.1007/s00259-017-3856-4. View

Marshall G, Carter D, Cheung B, Liu T, Mateos M, Meyerowitz J . The prenatal origins of cancer. Nat Rev Cancer. 2014; 14(4):277-89. PMC: 4041218. DOI: 10.1038/nrc3679. View

Steliarova-Foucher E, Colombet M, Ries L, Moreno F, Dolya A, Bray F . International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017; 18(6):719-731. PMC: 5461370. DOI: 10.1016/S1470-2045(17)30186-9. View

Sharp S, Gelfand M, Shulkin B . Pediatrics: diagnosis of neuroblastoma. Semin Nucl Med. 2011; 41(5):345-53. DOI: 10.1053/j.semnuclmed.2011.05.001. View

Southgate H, Chen L, Curtin N, Tweddle D . Targeting the DNA Damage Response for the Treatment of High Risk Neuroblastoma. Front Oncol. 2020; 10:371. PMC: 7145987. DOI: 10.3389/fonc.2020.00371. View

Casey D, Pitter K, Kushner B, Cheung N, Modak S, LaQuaglia M . Radiation Therapy to Sites of Metastatic Disease as Part of Consolidation in High-Risk Neuroblastoma: Can Long-term Control Be Achieved?. Int J Radiat Oncol Biol Phys. 2018; 100(5):1204-1209. PMC: 5934297. DOI: 10.1016/j.ijrobp.2018.01.008. View

Kreissman S, Seeger R, Matthay K, London W, Sposto R, Grupp S . Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. Lancet Oncol. 2013; 14(10):999-1008. PMC: 3963485. DOI: 10.1016/S1470-2045(13)70309-7. View

Smith M, Seibel N, Altekruse S, Ries L, Melbert D, OLeary M . Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010; 28(15):2625-34. PMC: 2881732. DOI: 10.1200/JCO.2009.27.0421. View

Papadimitriou N, Dimou N, Gill D, Tzoulaki I, Murphy N, Riboli E . Genetically predicted circulating concentrations of micronutrients and risk of breast cancer: A Mendelian randomization study. Int J Cancer. 2020; 148(3):646-653. PMC: 8268064. DOI: 10.1002/ijc.33246. View

10.

Olsson M, Beck S, Kogner P, Martinsson T, Caren H . Genome-wide methylation profiling identifies novel methylated genes in neuroblastoma tumors. Epigenetics. 2016; 11(1):74-84. PMC: 4846113. DOI: 10.1080/15592294.2016.1138195. View

11.

Chen W, Gao C, Liu Y, Wen Y, Hong X, Huang Z . Bioinformatics Analysis of Prognostic miRNA Signature and Potential Critical Genes in Colon Cancer. Front Genet. 2020; 11:478. PMC: 7296168. DOI: 10.3389/fgene.2020.00478. View

12.

Bartel D . Metazoan MicroRNAs. Cell. 2018; 173(1):20-51. PMC: 6091663. DOI: 10.1016/j.cell.2018.03.006. View

13.

Huntzinger E, Izaurralde E . Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 2011; 12(2):99-110. DOI: 10.1038/nrg2936. View

14.

Pottoo F, Abul Barkat M, Harshita , Ansari M, Noushad Javed M, Jamal Q . Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma. Semin Cancer Biol. 2019; 69:100-108. DOI: 10.1016/j.semcancer.2019.09.017. View

15.

Schmittgen T . Exosomal miRNA Cargo as Mediator of Immune Escape Mechanisms in Neuroblastoma. Cancer Res. 2019; 79(7):1293-1294. PMC: 7279940. DOI: 10.1158/0008-5472.CAN-19-0021. View

16.

De Preter K, Mestdagh P, Vermeulen J, Zeka F, Naranjo A, Bray I . miRNA expression profiling enables risk stratification in archived and fresh neuroblastoma tumor samples. Clin Cancer Res. 2011; 17(24):7684-92. PMC: 4008338. DOI: 10.1158/1078-0432.CCR-11-0610. View

17.

Yang C, Dou R, Yin T, Ding J . MiRNA-106b-5p in human cancers: diverse functions and promising biomarker. Biomed Pharmacother. 2020; 127:110211. DOI: 10.1016/j.biopha.2020.110211. View

18.

Qu H, Zheng L, Pu J, Mei H, Xiang X, Zhao X . miRNA-558 promotes tumorigenesis and aggressiveness of neuroblastoma cells through activating the transcription of heparanase. Hum Mol Genet. 2015; 24(9):2539-51. DOI: 10.1093/hmg/ddv018. View

19.

Cao X, Sun Z, Zhang L, Chen M, Yuan B . microRNA-144-3p suppresses human neuroblastoma cell proliferation by targeting HOXA7. Eur Rev Med Pharmacol Sci. 2019; 23(2):716-723. DOI: 10.26355/eurrev_201901_16885. View

20.

Cheng X, Xu Q, Zhang Y, Shen M, Zhang S, Mao F . miR-34a inhibits progression of neuroblastoma by targeting autophagy-related gene 5. Eur J Pharmacol. 2019; 850:53-63. DOI: 10.1016/j.ejphar.2019.01.071. View